Regeneron Pharmaceuticals Stock Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Regeneron Pharmaceuticals are completely uncorrelated. Although it is important to respect Regeneron Pharmaceuticals current trending patterns, it is better to be realistic regarding the information on the equity's existing price patterns. Our main philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Regeneron Pharmaceuticals technical indicators, you can presently evaluate if the expected return of 0.0% will be sustainable into the future.
Regeneron Performance
0 of 100
Over the last 90 days Regeneron Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Regeneron Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the insiders. ...more
| Begin Period Cash Flow | 2.9 B | |
| Total Cashflows From Investing Activities | -3.8 B |
Regeneron |
Regeneron Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.00 in Regeneron Pharmaceuticals on September 9, 2023 and sell it today you would earn a total of 0.00 from holding Regeneron Pharmaceuticals or generate 0.0% return on investment over 90 days. Regeneron Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Regeneron, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Regeneron Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regeneron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regeneron Pharmaceuticals, and traders can use it to determine the average amount a Regeneron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| REGN |
Based on monthly moving average Regeneron Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regeneron Pharmaceuticals by adding Regeneron Pharmaceuticals to a well-diversified portfolio.
Regeneron Pharmaceuticals Fundamentals Growth
Regeneron Stock prices reflect investors' perceptions of the future prospects and financial health of Regeneron Pharmaceuticals, and Regeneron Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regeneron Stock performance.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0921 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.36 % | ||||
| Current Valuation | 83.87 B | ||||
| Shares Outstanding | 107.13 M | ||||
| Price To Earning | 15.51 X | ||||
| Price To Book | 3.66 X | ||||
| Price To Sales | 7.01 X | ||||
| Revenue | 12.17 B | ||||
| Gross Profit | 7.02 B | ||||
| EBITDA | 5.17 B | ||||
| Net Income | 4.34 B | ||||
| Cash And Equivalents | 7.02 B | ||||
| Cash Per Share | 65.75 X | ||||
| Total Debt | 2.7 B | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 234.47 X | ||||
| Cash Flow From Operations | 5.01 B | ||||
| Earnings Per Share | 35.03 X | ||||
| Market Capitalization | 91.81 B | ||||
| Total Asset | 29.21 B | ||||
| Retained Earnings | 23.31 B | ||||
| Working Capital | 17.5 B | ||||
| Current Asset | 2.92 B | ||||
| Current Liabilities | 811.16 M | ||||
About Regeneron Pharmaceuticals Performance
To evaluate Regeneron Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Regeneron Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Regeneron Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Regeneron Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Regeneron's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for 2023 | ||
| Return on Investment | 20.55 | 21.00 | |
| Return on Average Assets | 0.16 | 0.17 | |
| Return on Average Equity | 0.20 | 0.24 | |
| Return on Invested Capital | 0.21 | 0.28 | |
| Return on Sales | 0.40 | 0.43 |
Things to note about Regeneron Pharmaceuticals performance evaluation
Checking the ongoing alerts about Regeneron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regeneron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regeneron Pharmaceuticals is not yet fully synchronised with the market data | |
| Regeneron Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 89.0% of the company shares are owned by institutional investors |
- Analyzing Regeneron Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regeneron Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Regeneron Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regeneron Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regeneron Pharmaceuticals' management team can help you assess the company's leadership.
- Pay attention to analyst opinions and ratings of Regeneron Pharmaceuticals' stock. These opinions can provide insight into Regeneron Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Tools for Regeneron Stock
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |